{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:57:35Z","timestamp":1781060255510,"version":"3.54.1"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Systemic inflammation, nutritional impairment, and immune dysregulation are important determinants of outcomes in advanced malignancies. The C-reactive protein\u2013albumin\u2013lymphocyte (CALLY) index is a composite biomarker that reflects these biological domains, but its prognostic relevance in de novo metastatic gastric adenocarcinoma has not been well defined. Materials and Methods: This multicenter retrospective cohort study included 234 patients with de novo metastatic gastric adenocarcinoma treated between January 2015 and December 2025. Baseline CALLY was calculated before systemic treatment. A cohort-specific CALLY threshold of 1.21 was obtained using conventional ROC analysis, with all-cause mortality status at last follow-up as the binary outcome. Survival was evaluated using Kaplan\u2013Meier analysis and Cox proportional hazards regression. To avoid guarantee-time bias, treatment exposure variables that became known only after treatment initiation, including the number of chemotherapy cycles delivered, were excluded from the baseline Cox models. Diagnosis period was included in the multivariable model to account for treatment-era heterogeneity. Results: Overall, 133 patients (56.8%) were classified as low-CALLY and 101 (43.2%) as high-CALLY. Median OS was significantly longer in the high-CALLY group than in the low-CALLY group (13.9 vs. 8.6 months; log-rank p &lt; 0.001). Low CALLY was associated with inferior OS in univariable analysis (HR: 1.77, 95% CI: 1.31\u20132.38; p &lt; 0.001) and remained associated with worse OS after adjustment for baseline clinicopathological factors, first-line treatment category, and diagnosis period (adjusted HR: 1.77, 95% CI: 1.24\u20132.53; p = 0.002). The PFS difference between the CALLY groups was not statistically significant (HR: 1.15, 95% CI: 0.87\u20131.51; p = 0.326). Conclusions: Low baseline CALLY was independently associated with shorter OS in this retrospective cohort. These findings support CALLY as a practical candidate prognostic biomarker, while external validation and time-to-event-based cut-off assessment are needed before clinical implementation.<\/jats:p>","DOI":"10.3390\/medicina62061124","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:58:12Z","timestamp":1781053092000},"page":"1124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The CALLY Index Is Associated with Overall Survival in Patients with De Novo Metastatic Gastric Adenocarcinoma"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-1093","authenticated-orcid":false,"given":"Fahri","family":"Akg\u00fcl","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, I\u011fd\u0131r Dr. Nevruz Erez State Hospital, I\u011fd\u0131r 76000, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9172-8571","authenticated-orcid":false,"given":"S\u00fcleyman","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, \u00c7anakkale Onsekiz Mart University, \u00c7anakkale 17100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-5396","authenticated-orcid":false,"given":"\u0130vo","family":"G\u00f6kmen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, \u00c7anakkale Onsekiz Mart University, \u00c7anakkale 17100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Bak\u0131r Kahveci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne 22030, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"Bayrak\u00e7\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne 22030, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dicle","family":"Yurdatap Ko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne 22030, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-9402","authenticated-orcid":false,"given":"Ece","family":"Demirdelen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne 22030, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-7659","authenticated-orcid":false,"given":"Veli","family":"\u00c7ak\u0131c\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, \u00c7anakkale Onsekiz Mart University, \u00c7anakkale 17100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne 22030, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00432-021-03902-1","article-title":"Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer","volume":"148","author":"Myer","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_7","first-page":"149","article-title":"Role of systemic inflammatory response in predicting survival in patients with primary operable cancer","volume":"36","author":"Roxburgh","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","first-page":"133","article-title":"Systemic inflammation, nutritional status and survival in patients with cancer","volume":"109","author":"McMillan","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_9","first-page":"1223","article-title":"A comparison of inflammation-based prognostic scores in patients with cancer","volume":"103","author":"Proctor","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wu, B., Liu, J., Shao, C., Yu, D., and Liao, J. (2025). Integrating inflammation, nutrition, and immunity: The CALLY index as a prognostic tool in digestive system cancers\u2014A systematic review and meta-analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14074-3"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1007\/s12094-025-03888-z","article-title":"Prognostic utility of the C-reactive protein-albumin-lymphocyte index (CALLY) in metastatic melanoma","volume":"27","author":"Acar","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112191","DOI":"10.1016\/j.nut.2023.112191","article-title":"Superiority of CRP-albumin-lymphocyte index as a prognostic biomarker for patients with gastric cancer","volume":"116","author":"Zhang","year":"2023","journal-title":"Nutrition"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.2147\/IJGM.S529776","article-title":"The prognostic and early efficacy prediction value of baseline CALLY index in advanced pancreatic cancer","volume":"18","author":"Zhu","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"582022","DOI":"10.2147\/BCTT.S582022","article-title":"Prognostic significance of the CRP-albumin-lymphocyte index (CALLY) in triple-negative breast cancer patients","volume":"18","author":"Liu","year":"2026","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12029-025-01307-8","article-title":"Prognostic value of CRP-albumin-lymphocyte (CALLY) index in colorectal cancer survival: A multicenter retrospective cohort study","volume":"56","author":"Bahardoust","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yang, M., Lin, S.Q., Liu, X.Y., Tang, M., Hu, C.L., Wang, Z.W., Zhang, Q., Zhang, X., Song, M.M., and Ruan, G.T. (2023). Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: From the investigation on nutrition status and clinical outcome of common cancers study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1131496"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Balci Topuz, B., Tufekci, A., Cangi, S., Yildirim, O.A., and Yildirim, M. (2026). The C-reactive protein-albumin-lymphocyte (CALLY) index as an independent predictor of progression and survival in metastatic renal cell carcinoma. J. Clin. Med., 15.","DOI":"10.3390\/jcm15041475"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fan, R., Lv, Z., Wang, T., Chen, W., Han, W., and Mei, Q. (2026). A compass in the challenge: The CALLY index as a prognostic biomarker in advanced cholangiocarcinoma treated with chemoimmunotherapy: A retrospective propensity score-matched cohort study. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1713495"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4062\/biomolther.2023.132","article-title":"C-reactive protein signaling pathways in tumor progression","volume":"31","author":"Kim","year":"2023","journal-title":"Biomol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"\u00d6zyurt, N., and Turhan, A. (2026). Prognostic impact of the Gustave Roussy Immune Score on cancer-specific survival and treatment completion in patients with bladder cancer. Diagnostics, 16.","DOI":"10.3390\/diagnostics16040574"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: An opportunity for combination with cytokines?","volume":"7","author":"Blay","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Akg\u00fcner, G., and Alt\u0131nba\u015f, M. (2025). Prognostic utility of the C-reactive protein-albumin-lymphocyte (CALLY) index in metastatic renal cell carcinoma. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14767-9"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hpb.2021.06.414","article-title":"Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma","volume":"24","author":"Iida","year":"2022","journal-title":"HPB"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Li, H., Mo, Z., and Tong, G. (2025). Value of CRP, albumin, and lymphocyte index in predicting survival of patients with gastrointestinal malignancies: A systematic review and meta-analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1592794"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.21873\/invivo.13518","article-title":"Clinical impact of the C-reactive protein-albumin-lymphocyte index in post-gastrectomy patients with gastric cancer","volume":"38","author":"Hashimoto","year":"2024","journal-title":"In Vivo"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.16873","article-title":"CRP-albumin-lymphocyte (CALLY) index is an independent prognostic factor for esophageal cancer patients who received curative treatment","volume":"44","author":"Aoyama","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00595-024-02813-1","article-title":"Prognostic significance of the preoperative C-reactive protein-albumin-lymphocyte (CALLY) index on outcomes after gastrectomy for gastric cancer","volume":"54","author":"Fukushima","year":"2024","journal-title":"Surg. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.gassur.2024.04.016","article-title":"Clinical feasibility of the preoperative C-reactive protein-albumin-lymphocyte index to predict short- and long-term outcomes of patients with gastric cancer","volume":"28","author":"Okugawa","year":"2024","journal-title":"J. Gastrointest. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1177\/00031348241248693","article-title":"Usefulness of the C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index as a prognostic indicator for patients with gastric cancer","volume":"90","author":"Nakashima","year":"2024","journal-title":"Am. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kim, K.W., Lee, H.Y., Lee, J.I., and Lee, E.C. (2026). Prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index in surgically treated non-small cell lung cancer. Front. Nutr., 13.","DOI":"10.3389\/fnut.2026.1784875"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/hon.3002","article-title":"Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma","volume":"40","author":"Mancuso","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:04:21Z","timestamp":1781057061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061124"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061124","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}